Drug company Shenzhen Chipscreen Biosciences Co Ltd (Stock Symbol: 688321.SH) revealed on Friday that its lead innovative product Epidaza (Chidamide) has now received National Medical Products Administration (NMPA) approval for the breast cancer marketing application, reflecting its second indication.
The company said Epidaza (Chidamide) was previously approved for recurrent and refractory peripheral T cell lymphoma in China.
According to the company, Chidamide is combined with aromatase inhibitor in postmenopausal patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer (ABC) treated with endocrine therapies for recurrence or progression.
Chidamide is a selective HDAC inhibitor with unique epigenetic mechanisms against tumour cell growth, immune escape and drug resistance. In a pivotal phase 3 clinical trial, chidamide in combination with exemestane has demonstrated progression-free survival benefit and manageable adverse effects in postmenopausal patients with advanced, hormone receptor-positive breast cancer, added the company.
Breast cancer is the most common female malignancy in the world and China. In 2017, China's cancer registry annual report showed that the incidence of new breast cancer cases in China was 279,000, annually increased by 2%.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients